Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lisa Ricciardi
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 1.80
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.00
Financials
Net Income
$-4.14MEBITDA
$-4.11MFree Cash Flow
$-3.26M-726.7%EPS (diluted)
$-0.04Shares Outstanding (diluted)
95.10M+353.8%Operating Expenses
$7.38MCash & Debt
$30.76MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-23.49M | $-0.32 |
| 2024 | $0.00 | $-33.97M | $-0.85 |
| 2023 | $0.00 | $-25.79M | $-0.86 |
| 2022 | $0.00 | $757.0K | $-0.74 |
| 2021 | $0.00 | $-11.72M | $-0.73 |
| 2020 | $0.00 | $-10.07M | $-0.55 |
| 2019 | $0.00 | $-6.95M | $-0.32 |
Valuation
CGTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
20-60.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·5d ago·Negative
… participant and site burden in clinical trials - PURCHASE, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that our partners at the Alzheimer's Clinical Trials Consortium (ACTC) are presenting an Alzheimer's disease screening strategy that may reduce the burden on participants and clinical sites.
View source ↗ - Newszacks.com·12d ago·Positive
What Makes Cognition Therapeutics (CGTX) a New Buy Stock Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·17d ago·Negative
Cognition Therapeutics Q3 Earnings Call Highlights Cognition Therapeutics NASDAQ: CGTX is preparing a Phase III trial of its experimental drug zervimesine in dementia with Lewy bodies after reaching alignment with the U.S. Food and Drug Administration on a planned registrational study, executives said on the company's third-quarter 2026 earnings call.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
…on November 5, 2026 -- Conference Call and Webcast 8:30 a.m. ET November 5 -- PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, a…
View source ↗ - Newsglobenewswire.com·31d ago·Negative
…Zervimesine (CT1812) in Dementia with Lewy Bodies PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient selection, dose, duration, and endpoints.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 - An additional five years of patent protection may be possible through a standard extension - - An additional five years of patent protection may be possible through a standard extension -
View source ↗
Earnings
Thu, Mar 25(in 4 months)
Consensus estimate $-0.07 per share
Typical surprise +16.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.04 vs $-0.07beat
- Thu, Aug 6$-0.04 vs $-0.06beat
- Thu, May 7$-0.05 vs $-0.06beat
- Thu, Mar 26$-0.02 vs $-0.06beat
- Thu, Nov 6$-0.06 vs $-0.07beat
- Thu, Aug 7$-0.11 vs $-0.12beat
Estimates and results for CGTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CGTX officers and directors.
- Bought
- $179k
- Sold
- —
11 trades
0 trades
- Doyle John Brendanbought
- Ricciardi Lisabought
- Caggiano Anthonybought
- Ricciardi Lisabought
- Ricciardi Lisabought
- Richstone Ellen Bbought
- Fletcher Aaron G.l.bought
- Fletcher Aaron G.l.bought
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CGTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
